Lily Morris was diagnosed with acute lymphoblastic leukaemia (ALL) in 2022 aged 15. Now 16, she tells us about its impact on her GCSE preparations, and the support she’s received from her school and friends as she transitioned back into full-time education.
Charlotte Bowling's daughter, Amelie, was diagnosed with acute lymphoblastic leukaemia (ALL) in June 2019 aged six. Charlotte tells us about the support her daughter and her family received from her school, including an innovative way of ensuring Amelie was involved even when not physically present.
Ruby Abramow was first diagnosed with a rare head and neck cancer aged nine, before relapsing in 2019, when she was 14. Now 19, she tells us how a new, supportive environment gave her the fresh start she needed to take back control of her disrupted education.
Parents and carers of children who have been diagnosed with cancer often have many questions about school and education. Keeley McEvoy, Lead Assistant Headteacher of the Medical Needs Teaching Service working at Leeds Children’s Hospital, explains more about what to expect from hospital teaching, ongoing education support and transitioning back to school.
Naomi Duxbury’s daughter, Mia, was aged four when diagnosed with B-cell acute lymphoblastic leukaemia in September 2021. Here, she tells us about the importance of working closely with Mia’s school to create a safe, supportive and ‘normal’ learning environment for her.
Children with cancer who also have learning difficulties and autism often have additional needs when it comes to their care. Jeanette Hawkins, CCLG’s Chief Nurse, tells us more about a project aiming to improve support for this group of patients.
Gareth Veal, Professor of Cancer Pharmacology at the Newcastle University Cancer Centre, leads a team helping doctors to personalise treatments through an innovative process called ‘therapeutic drug monitoring’. Here, he tells us more about his work.
Molecular radiotherapy (MRT) is an evolving form of children’s cancer treatment. Dr Mark Gaze, Caroline Elmagrahi and Georgia Azzopardi, of University College London Hospitals NHS Foundation Trust, tell us more about what it is and what work is being done to develop its usage.
Artificial intelligence (AI) has helped scientists propose a promising new drug combination for DIPG brain tumours. Prof Chris Jones, Director of the Brain Tumour Research Centre of Excellence at the Institute of Cancer Research (ICR), and Dr Fernando Carceller, Paediatric Neuro-Oncology Consultant at The Royal Marsden Hospital, tell us more.
